INTERFERON GAMMA SIGNALING DEFECTS IN TUMOR EVASION
INTERFERON GAMMA SIGNALING DEFECTS IN TUMOR EVASION
批准号:
6563893
负责人:
ROBERT DAVID SCHREIBER
金额:
$19.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-12-01 至 2002-11-30
关键词:
CD2 molecule T cell receptor T lymphocyte antibody specificity biological signal transduction cell line cytokine receptors gene mutation genetically modified animals human tissue immune tolerance /unresponsiveness immunogenetics interferon gamma laboratory mouse leukocyte activation /transformation macrophage molecular shape natural killer cells neoplasm /cancer genetics neoplasm /cancer immunology nuclear runoff assay protein structure function receptor expression tumor suppressor proteins
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Recently, we made the novel observation that endogenously produced
IFNgamma exerts direct effects on tumor cells in mice that result in
enhanced recognition and elimination of the tumor by the immune system.
This data implies that IFNgamma forms the basis of a tumor surveillance
system in immunocompetent hosts. We have also found that certain types of
tumors become IFNgamma unresponsive and may thereby escape immune
recognition. The overall focus of this grant application is to define
IFNgamma's effects on tumors that result in enhanced immune
recognition/elimination and to elucidate the genetic and acquired
mechanisms used by tumors to circumvent the process. To achieve this goal
we intend to pursue the following four specific aims. Specific Aim 1:
Define the participation of IFNgamma in mediating tumor surveillance in
mice. We will better define the process of IFNgamma dependent tumor
surveillance and assess the relative importance of IFNgamma's effect on
nascently forming transformed cells and host immune cells. Specific Aim 2:
Define the defect(s) in IFNgamma insensitive tumors that render them
resistant to immune elimination. We will determine whether IFNgamma
insensitivity at the level of the tumor influences antigen processing
and/or presentation, co-stimulation, T cell-target cell contact and/or
sensitivity of the tumor to T cell killing processes. Specific Aim 3:
Assess the role of IFNgamma receptor beta chain mechanism underlying our
recent observation that IFNgamma desensitizes tumor cells and macrophages
to subsequent IFNgamma treatment giving particular emphasis to the likely
possibility that this process is the result of ligand induced in tumor
cells is a common or rare event during tumorigenesis and define the
molecular basis of IFNgamma unresponsiveness in human and murine tumors.
We will (a) determine whether tumors formed in IFNgamma sensitive mice or
human cancer patients develop genetic or adaptive insensitivity to
IFNgamma and (b) characterize the molecular basis of the IFNgamma
signaling defects found in four IFNgamma insensitive human lung
adenocarcinoma cell lines that we have already identified. Taken together
these studies should provide us with important insights into the role of
IFNgamma in promoting immune responses to tumors and into the strategies
used by tumors to escape IFNgamma's actions. Understanding the latter
process will be particularly important in the development of new IFNgamma
based therapeutic or diagnostic strategies to be used in treatment of
cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPY
-
批准号:8887618
-
项目类别:
-
资助金额:$46.91万
-
财政年份:2015
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
DEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPY
-
批准号:9031745
-
项目类别:
-
资助金额:$44.9万
-
财政年份:2015
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Genetics Core
-
批准号:8379365
-
项目类别:
-
资助金额:$23.36万
-
财政年份:2012
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Tissue specific role of IFNalpha/beta and IFNgamma in innate immuniy to prio path
-
批准号:8234935
-
项目类别:
-
资助金额:$36.23万
-
财政年份:2011
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Tumor Immunology Program
-
批准号:8181178
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2010
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Tissue specific role of IFNalpha/beta and IFNgamma in innate immuniy to prio path
-
批准号:7672130
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2009
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Genetic Core
-
批准号:7667781
-
项目类别:
-
资助金额:$20.78万
-
财政年份:2008
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Genetic Core
-
批准号:7485263
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2007
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
The Molecular and Cellular Basis of Cancer Immunoediting
-
批准号:6771282
-
项目类别:
-
资助金额:$39.5万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
The Molecular and Cellular Basis of Cancer Immunoediting
-
批准号:7215633
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
The Molecular and Cellular Basis of Cancer Immunoediting
-
批准号:6888072
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Jaks and Stats: Development to Disease
-
批准号:6789526
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
The Molecular and Cellular Basis of Cancer Immunoediting
-
批准号:7028854
-
项目类别:
-
资助金额:$40.64万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
The Molecular and Cellular Basis of Cancer Immunoediting
-
批准号:7361384
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
Tumor Immunology Program
-
批准号:6998150
-
项目类别:
-
资助金额:$2.03万
-
财政年份:2004
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
IL-10 Receptor Signaling That Regulates Innate Immunity
-
批准号:6718020
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2003
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
IL-10 Receptor Signaling That Regulates Innate Immunity
-
批准号:6984102
-
项目类别:
-
资助金额:$41.32万
-
财政年份:2003
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
IL-10 Receptor Signaling That Regulates Innate Immunity
-
批准号:6833471
-
项目类别:
-
资助金额:$41.01万
-
财政年份:2003
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
IL-10 Receptor Signaling That Regulates Innate Immunity
-
批准号:7325725
-
项目类别:
-
资助金额:$41.76万
-
财政年份:2003
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
IL-10 Receptor Signaling That Regulates Innate Immunity
-
批准号:7151927
-
项目类别:
-
资助金额:$41.33万
-
财政年份:2003
-
负责人:ROBERT DAVID SCHREIBER
-
依托单位:
海外基金